Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia



Status:Active, not recruiting
Conditions:Cancer, Blood Cancer, Anemia, Leukemia
Therapuetic Areas:Hematology, Oncology
Healthy:No
Age Range:18 - Any
Updated:3/14/2019
Start Date:January 29, 2009

Use our guide to learn which trials are right for you!

Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment With Lenalidomide (Revlimid®) Alone and in Combination With Epoetin Alfa (Procrit®) in Subjects With Low- or Intermediate-1 Risk MDS and Symptomatic Anemia

This randomized phase III trial studies lenalidomide to see how well it works with or without
epoetin alfa in treating patients with myelodysplastic syndrome and anemia. Lenalidomide may
stop the growth of myelodysplastic syndrome by blocking blood flow to the cells. Colony
stimulating factors, such as epoetin alfa, may increase the number of immune cells found in
bone marrow or peripheral blood. It is not yet known whether lenalidomide is more effective
with or without epoetin alfa in treating patients with myelodysplastic syndrome and anemia.

PRIMARY OBJECTIVES:

I. To compare the rate of major erythroid response (MER) between lenalidomide monotherapy and
combined treatment of lenalidomide and epoetin alfa in erythropoietin non-responsive
low-/intermediate-1 (Int-1)-risk myelodysplastic syndrome (MDS) patients or erythropoietin
treatment naïve patients with low probability of erythropoietin benefit.

SECONDARY OBJECTIVES:

I. To compare the time to MER by treatment assignment. II. To evaluate the duration of MER by
treatment assignment. III. To estimate the frequency of MER to salvage combination therapy in
patients who fail to experience a MER with lenalidomide monotherapy.

IV. To evaluate and compare the frequency of minor erythroid response by treatment
assignment.

V. To investigate the mechanism and target of lenalidomide action in patients with chromosome
5q31.1 deletion.

VI. To evaluate the frequency of cytogenetic response and progression, and the relationship
between cytogenetic pattern and erythroid response.

VII. To evaluate the frequency of bone marrow response (complete response [CR] + partial
response [PR]).

VIII. To evaluate the relationship between erythroid response and laboratory correlates
outlined below: pretreatment and on study endogenous erythropoietin level (Arm A); to
evaluate the effect of CD45 isoform profile on lenalidomide enhancement of
erythropoietin-induced STAT5 phosphorylation in CD71^Hi erythroid precursors and the
relationship to erythroid response; to characterize molecular targets relevant to
lenalidomide cytotoxicity in del5q31.1 cells; to evaluate the frequency of cryptic chromosome
5q31.1 deletions in patients with non-del5q31.1 MDS by array-based genomic scan, and to
determine the relationship to hematologic response.

OUTLINE: Patients are randomized to 1 of 2 treatment arms. Patients with del 5q31.1 karyotype
are assigned to Arm A.

ARM A: Patients receive lenalidomide orally (PO) once daily (QD) on days 1-21.

ARM B: Patients receive lenalidomide PO QD on days 1-21 and epoetin alfa subcutaneously (SC)
once weekly.

In both arms, treatment repeats every 28 days for 4 courses. Patients who achieve a major
erythroid response (MER) may continue treatment beyond 4 courses in the absence of disease
progression, disease conversion to acute myeloid leukemia, or unacceptable toxicity. Patients
in Arm A who fail to achieve MER or who achieve MER but relapse after 16 weeks of treatment
with lenalidomide may crossover and receive treatment in Arm B.

After completion of study treatment, patients are followed up for 6 months.

Inclusion Criteria:

- NOTE: Results of the bone marrow biopsy and aspirate as well as cytogenetics are
mandatory to register subjects onto study, which are indispensable to determine
International Prognostic Scoring System (IPSS) category needed for eligibility; please
note that it is not necessary to wait for the week 16, week 32, or week bone marrow
and cytogenetic results prior to starting the next cycle unless deemed necessary by
the treating physician; one example of this exception can include if the subject shows
signs of progression, such as increased peripheral blood blast percentage; at that
juncture, the treating physician may prefer to await the results prior to starting a
new cycle; if a cycle is started, and based on the bone marrow results it is felt by
the treating physician that the subject should not continue on treatment, please be
sure to note this information on the case report forms at end of treatment

- Patient must have documented diagnosis of MDS lasting at least three months (MDS
duration >= 3 months) according to World Health Organization (WHO) criteria or
non-proliferative chronic myelomonocytic leukemia (CMML) (white blood cell [WBC] <
12,000/mcL)

- Patient must have IPSS categories of low- or intermediate-1-risk disease; patients
must have IPSS score determined by cytogenetic analysis prior to randomization;
patients must have cytogenetic analysis done (to calculate IPSS); if the current bone
marrow biopsy is a dry tap, patients with cytogenetic failure and < 10% marrow blasts
will be eligible; subjects with cytogenetic failure must have previous cytogenetic
results (fluorescence in situ hybridization [FISH] is not a substitute) within the
last 6 months post last type of MDS treatment (in this case, not referring to growth
factors as type of MDS treatment)

- Must have symptomatic anemia untransfused with hemoglobin < 9.5 g/dL =< 8 weeks prior
to randomization or with red blood cells (RBC) transfusion dependence (i.e., >= 2
units/month) confirmed for =< 8 weeks before randomization

- NOTE: For non-transfusion dependent patients (i.e., receiving < 2 units/4 weeks x
8 weeks pre-study) who receive periodic transfusions, the mean 8 week
pre-transfusion hemoglobin should be used to determine protocol eligibility and
response reference

- For non-transfusion dependent patients, a minimum of 2 pre-transfusion or
un-transfused hemoglobin values are required

- Applies only for patients without the deletion 5q 31.1; patients must have failed
treatment with an erythropoietic growth factor, or have a low probability of response
to rhu-erythropoietin; patients with low probability of response to rhu-erythropoietin
or prior erythropoietin failures are defined as follows:

- Prior erythropoietin failure-requires a minimum trial of >= 40,000 units epoetin
alfa/week x 8 weeks or equivalent dose of darbepoetin alfa for 8 weeks with
failure to achieve transfusion independence in dependent patients or a failure to
achieve a >= 2 g rise in hemoglobin sustained for >= 4 weeks in non-transfusion
dependent patients

- Low erythropoietin response profile-rhu-erythropoietin and epoetin alfa-naïve
patients receiving >= 2U packed (p)RBC/month for a minimum of 8 weeks, and serum
erythropoietin > 500 mU/mL in the 8 weeks prior to randomization for a hemoglobin
< 9.5 g/dL

- Patients must be off all non-transfusion therapy for MDS for 28 days prior to
initiation of study treatment, including all types of growth factors; patients may
receive hydrocortisone prophylactically to prevent transfusion reactions

- Patients must have a serum erythropoietin level documented before randomization and =<
56 days before day 1 of study treatment; NOTE: hemoglobin must be < 9.5 g/dL at time
that serum erythropoietin is drawn

- Patients must not have documented iron deficiency; all patients must have documented
marrow iron stores; if marrow iron stain is not available, the transferrin saturation
must be > 20% or a serum ferritin > 100 ng/mL

- Women must not be pregnant or breastfeeding; females of childbearing potential must
have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL
within 10-14 days and again within 24 hours prior to starting cycle 1 of lenalidomide;
a female of childbearing potential (FCBP) is any woman, regardless of sexual
orientation or whether they have undergone tubal ligation, who meets the following
criteria: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not
been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses
at any time in the preceding 24 consecutive months; FCBP must also agree to ongoing
pregnancy testing)

- Effective contraception must be used by patients participating in lenalidomide
therapy, and all patients must agree to counseling by a trained counselor every 28
days about pregnancy precautions and risks of fetal exposure; females of childbearing
potential (FCBP) must either commit to continued abstinence from heterosexual
intercourse or begin TWO acceptable methods of birth control: one highly effective
method and one additional effective method AT THE SAME TIME, at least 28 days before
starting lenalidomide, during lenalidomide therapy, during dose interruptions, and for
at least 28 days following discontinuation of lenalidomide therapy; females of
childbearing potential should be referred to a qualified provider of contraceptive
methods, if needed; males receiving lenalidomide must agree to use a latex condom
during any sexual contact with females of childbearing potential even if they have
undergone a successful vasectomy

- Patients must not have prior therapy with lenalidomide

- Patients must not have a diagnosis of uncontrolled seizure or uncontrolled
hypertension

- Patients must not have proliferative (WBC >= 12,000/mcL) chronic myelomonocytic
leukemia (CMML); WBC must be < 12,000/mcL

- Patients must not have MDS secondary to treatment with radiotherapy, chemotherapy,
and/or immunotherapy for malignant or autoimmune diseases

- Within 56 days prior to randomization: Platelet count >= 50,000/mcL (50 x 10^9/L)
without platelet transfusion

- Within 56 days prior to randomization: Absolute neutrophil count (ANC) >= 500
cells/mcL (0.5 x 10^9/L); hence ANC must be >= 500/mcL without myeloid growth factor
support

- Within 56 days prior to randomization: Serum creatinine =< 1.5 times upper limit of
normal (ULN)

- Within 56 days prior to randomization: Serum glutamic oxaloacetic transaminase
(SGOT)/aspartate aminotransferase (AST) or serum glutamate pyruvate transaminase
(SGPT)/alanine aminotransferase (ALT) =< 2.0 x ULN

- Within 56 days prior to randomization: Serum total bilirubin < 3.0 mg/dL

- Prior thalidomide is allowed, however, patients must not have prior >= grade-3
allergic reactions to thalidomide

- Patients must not have prior history of desquamating rash from thalidomide at time of
study entry

- Patients must not have clinically significant anemia resulting from iron, B12 or
folate deficiencies, autoimmune or hereditary hemolysis, or gastrointestinal bleeding

- Patients must not have used cytotoxic chemotherapeutic agents or experimental agents
(agents that are not commercially available) for the treatment of MDS within 8 weeks
of randomization

- Patients must not have prior history of malignancy other than MDS (except basal cell
or squamous skin cell carcinoma or carcinoma in situ of the cervix or breast) unless
the subject has been confirmed free of disease for >= 3 years

- Patients must not have any serious medical condition or any other unstable medical
co-morbidity, or psychiatric illness that will prevent the subject from signing the
informed consent form or will place the subject at unacceptable risk if he/she
participates in the study

- Patients must not have a history of thrombo-embolic events within 3 years prior to
study randomization

- Patients must not have known human immunodeficiency virus (HIV)-1 seropositivity

- Patients must not have a known allergic reaction to epoetin alfa (Procrit) or human
serum albumin

- Eligibility for crossover registration from Arm A (lenalidomide alone) to Arm B
(lenalidomide and epoetin alfa):

- Patients must have completed 16 weeks of monotherapy with lenalidomide

- Patients must show failure to achieve MER (major erythroid response) or have achieved
MER but relapsed on Arm A

- Patients must not have a limiting unresolved grade 3 or greater toxicity from
lenalidomide monotherapy or drug intolerance preventing continuation of lenalidomide
treatment
We found this trial at
515
sites
La Porte, Indiana 46350
?
mi
from
La Porte, IN
Click here to add this to my saved trials
1300 Jefferson Park Avenue
Charlottesville, Virginia 22908
434-243-6784
University of Virginia Cancer Center We are fortunate in having state of the art clinical...
?
mi
from
Charlottesville, VA
Click here to add this to my saved trials
1 Hurley Plaza
Flint, Michigan 48503
(810) 262-9000
Hurley Medical Center From its founding in 1908, Hurley Medical Center has devoted itself to...
?
mi
from
Flint, MI
Click here to add this to my saved trials
4725 North Federal Highway
Fort Lauderdale, Florida 33308
(954) 771-8000
Holy Cross Hospital While spirituality plays an essential role in the way that we minister...
?
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
Jupiter, Florida 33458
?
mi
from
Jupiter, FL
Click here to add this to my saved trials
524 South Park Street
Kalamazoo, Michigan 49007
(269) 341-7654
Bronson Methodist Hospital Our healthcare system serves patients and families throughout southwest Michigan and northern...
?
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
200 North Park Street
Kalamazoo, Michigan 49007
(269) 382-2500
Principal Investigator: Sunil Nagpal
Phone: 269-373-7458
West Michigan Cancer Center In 1994, Borgess Health Alliance and Bronson Healthcare Group opened the...
?
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
1800 West Charleston Boulevard
Las Vegas, Nevada 89102
(702) 383-2000
University Medical Center of Southern Nevada University Medical Center is dedicated to providing the highest...
?
mi
from
Las Vegas, NV
Click here to add this to my saved trials
600 East Dixie Avenue
Leesburg, Florida 34748
Principal Investigator: Pablo C. Reyes
?
mi
from
Leesburg, FL
Click here to add this to my saved trials
4805 Northeast Glisan Street
Portland, Oregon 97213
(503) 215-1111
Principal Investigator: Keith S. Lanier
Phone: 503-216-6324
Providence Portland Medical Center We strive to give those we serve exceptional, compassionate health care...
?
mi
from
Portland, OR
Click here to add this to my saved trials
60 Crittenden Blvd # 70
Rochester, New York 14642
(585) 275-2121
Principal Investigator: Jonathan W. Friedberg
Phone: 585-275-5830
University of Rochester The University of Rochester is one of the country's top-tier research universities....
?
mi
from
Rochester, NY
Click here to add this to my saved trials
3900 W Avera Drive
Sioux Falls, South Dakota 57108
(605) 322-4700
Avera Cancer Institute Avera, the health ministry of the Benedictine and Presentation Sisters, is a...
?
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
601 South Sherman Street
Spokane, Washington 99202
(509) 228-1000
Cancer Care Northwest - Spokane South Cancer Care Northwest is the Inland Northwest’s premier cancer...
?
mi
from
Spokane, WA
Click here to add this to my saved trials
1200 Old York Road
Abington, Pennsylvania 19001
(215) 481–2000
Principal Investigator: Willard G. Andrews
Phone: 215-481-2402
Abington Memorial Hospital Abington Memorial Hospital (AMH) is a 665-bed, regional referral center and teaching...
?
mi
from
Abington, PA
Click here to add this to my saved trials
Adrian, Michigan 49221
?
mi
from
Adrian, MI
Click here to add this to my saved trials
818 Riverside Ave.
Adrian, Michigan 49221
(517) 265-0900
Bixby Medical Center ProMedica's Mission is to improve your health and well-being. Which is why,...
?
mi
from
Adrian, MI
Click here to add this to my saved trials
Alexandria, Minnesota 56308
?
mi
from
Alexandria, MN
Click here to add this to my saved trials
?
mi
from
Amarillo, TX
Click here to add this to my saved trials
Ames, Iowa 50010
?
mi
from
Ames, IA
Click here to add this to my saved trials
Anaheim, California 92806
?
mi
from
Anaheim, CA
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Keith S. Lanier
Phone: 503-216-6324
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Keith S. Lanier
Phone: 503-216-6324
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Keith S. Lanier
Phone: 503-216-6324
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Keith S. Lanier
Phone: 503-216-6324
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Keith S. Lanier
Phone: 503-216-6324
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
5301 McAuley Drive
Ann Arbor, Michigan 48197
734-712-3456
Principal Investigator: Philip J. Stella
Phone: 734-712-4673
Saint Joseph Mercy Hospital St. Joseph Mercy Ann Arbor Hospital is a 537-bed teaching hospital...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Ann Arbor, Michigan 48106
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
1500 East Medical Center Drive
Ann Arbor, Michigan 48109
800-865-1125
University of Michigan Comprehensive Cancer Center The U-M Comprehensive Cancer Center's mission is the conquest...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Appleton, Wisconsin 54913
Principal Investigator: Timothy F. Goggins
Phone: 920-749-1171
?
mi
from
Appleton, WI
Click here to add this to my saved trials
Asheville, North Carolina 28801
?
mi
from
Asheville, NC
Click here to add this to my saved trials
Ashland, Kentucky 41101
?
mi
from
Ashland, KY
Click here to add this to my saved trials
Augusta, Georgia 30912
?
mi
from
Augusta, GA
Click here to add this to my saved trials
1501 S Potomac St
Aurora, Colorado 80012
(303) 695-2600
Medical Center of Aurora At The Medical Center of Aurora and Centennial Medical Plaza patients...
?
mi
from
Aurora, CO
Click here to add this to my saved trials
Baldwin Park, California 91706
Principal Investigator: Gary L. Buchschacher
Phone: 323-783-1401
?
mi
from
Baldwin Park, CA
Click here to add this to my saved trials
Baltimore, Maryland 21229
Principal Investigator: Carole B. Miller
Phone: 410-368-2910
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
401 North Broadway
Baltimore, Maryland 21287
410-955-5000
Principal Investigator: Amy E. DeZern
Phone: 410-955-8804
Johns Hopkins University-Sidney Kimmel Cancer Center The name Johns Hopkins has become synonymous with excellence...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
22 South Greene Street
Baltimore, Maryland 21201
410-328-7904
University of Maryland Greenebaum Cancer Center The University of Maryland Marlene and Stewart Greenebaum Cancer...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
4305 New Shepherdsville Road
Bardstown, Kentucky 40004
Principal Investigator: Mehmet S. Copur
Phone: 800-998-2119
?
mi
from
Bardstown, KY
Click here to add this to my saved trials
Beech Grove, Indiana 46107
?
mi
from
Beech Grove, IN
Click here to add this to my saved trials
Bellflower, California 90706
?
mi
from
Bellflower, CA
Click here to add this to my saved trials
Bellingham, Washington 98225
?
mi
from
Bellingham, WA
Click here to add this to my saved trials
8901 Rockville Pike
Bethesda, Maryland 20889
(301) 295-4000
Principal Investigator: Mary L. Kwok
Phone: 301-295-0981
Walter Reed National Military Medical Center The Walter Reed National Military Medical Center is one...
?
mi
from
Bethesda, MD
Click here to add this to my saved trials
Billings, Montana 59101
?
mi
from
Billings, MT
Click here to add this to my saved trials
?
mi
from
Billings, MT
Click here to add this to my saved trials
Billings, Montana 59101
Principal Investigator: Benjamin T. Marchello
Phone: 800-648-6274
?
mi
from
Billings, MT
Click here to add this to my saved trials
1233 North 30th Street
Billings, Montana 59101
406-237-7000
Saint Vincent Healthcare The Sisters of Charity of Leavenworth, Kansas, founded St. Vincent Healthcare in...
?
mi
from
Billings, MT
Click here to add this to my saved trials
Billings, Montana 59102
?
mi
from
Billings, MT
Click here to add this to my saved trials
Birmingham, Alabama 35233
Principal Investigator: Harry P. Erba
Phone: 205-975-3910
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
900 E Broadway Ave
Bismarck, North Dakota 58501
(701) 530-5550
Mid Dakota Clinic, PC We're your family clinic, with the doctors you know and trust...
?
mi
from
Bismarck, ND
Click here to add this to my saved trials
900 East Broadway
Bismarck, North Dakota 58501
701.530.7000
Saint Alexius Medical Center St. Alexius Medical Center is a 306-bed, full-service, acute care medical...
?
mi
from
Bismarck, ND
Click here to add this to my saved trials
300 N. Seventh St.
Bismarck, North Dakota 58501
(701) 323-6000
Sanford Bismarck Medical Center Whether your stay in our hospital is one day for same...
?
mi
from
Bismarck, ND
Click here to add this to my saved trials
1505 Eastland Drive
Bloomington, Illinois 61701
309-662-2102
Principal Investigator: James L. Wade
Phone: 217-876-4740
Illinois CancerCare-Bloomington Illinois CancerCare, P.C. is a comprehensive practice treating patients withcancer andblood diseases. Our...
?
mi
from
Bloomington, IL
Click here to add this to my saved trials
Boise, Idaho 83706
Principal Investigator: Philip J. Stella
Phone: 734-712-4673
?
mi
from
Boise, ID
Click here to add this to my saved trials
100 E Idaho St
Boise, Idaho 83712
(208) 381-2711
Principal Investigator: Keith S. Lanier
Phone: 503-216-6324
Saint Luke's Mountain States Tumor Institute For more than 100 years, St. Luke
?
mi
from
Boise, ID
Click here to add this to my saved trials
1100 Balsam Ave
Boulder, Colorado 80304
(303) 440-2273
Boulder Community Hospital Founded in 1922 as a community-owned and operated not-for-profit hospital, Boulder Community...
?
mi
from
Boulder, CO
Click here to add this to my saved trials
960 W Wooster St
Bowling Green, Ohio 43402
419-353-5419
Toledo Clinic Cancer Centers-Bowling Green Our doctors evaluate and make recommendations regarding cancer treatment for...
?
mi
from
Bowling Green, OH
Click here to add this to my saved trials
915 Highland Blvd
Bozeman, Montana 59715
(406) 414-5000
Principal Investigator: Benjamin T. Marchello
Phone: 800-648-6274
Bozeman Deaconess Hospital Bozeman Deaconess Hospital is a Joint Commission certified, licensed Level III trauma...
?
mi
from
Bozeman, MT
Click here to add this to my saved trials
?
mi
from
Bremerton, WA
Click here to add this to my saved trials
Brighton, Massachusetts 02135
?
mi
from
Brighton, MA
Click here to add this to my saved trials
?
mi
from
Bronx, NY
Click here to add this to my saved trials
?
mi
from
Bronx, NY
Click here to add this to my saved trials
130 S Bryn Mawr Ave
Bryn Mawr, Pennsylvania 19010
(484) 337-3000
Bryn Mawr Hospital Bryn Mawr Hospital, a nationally recognized community teaching hospital, is conveniently located...
?
mi
from
Bryn Mawr, PA
Click here to add this to my saved trials
Burbank, California
Principal Investigator: Keith S. Lanier
Phone: 503-216-6324
?
mi
from
Burbank, CA
Click here to add this to my saved trials
Burlington, Massachusetts 01805
Principal Investigator: Alan F. List
Phone: 813-745-7101
?
mi
from
Burlington, MA
Click here to add this to my saved trials
Burlington, Wisconsin 53105
?
mi
from
Burlington, WI
Click here to add this to my saved trials
201 E Nicollet Blvd
Burnsville, Minnesota 55337
(952) 892-2000
Principal Investigator: Patrick J. Flynn
Phone: 952-993-1517
Fairview Ridges Hospital Fairview Ridges Hospital is a 150-bed, Level III Trauma Care facility, offering...
?
mi
from
Burnsville, MN
Click here to add this to my saved trials
Butler, Pennsylvania 16001
?
mi
from
Butler, PA
Click here to add this to my saved trials
400 South Clark Street
Butte, Montana 59701
406-723-2500
Principal Investigator: Benjamin T. Marchello
Phone: 800-648-6274
Saint James Community Hospital and Cancer Treatment Center St. James Healthcare has played an important...
?
mi
from
Butte, MT
Click here to add this to my saved trials
?
mi
from
Camden, NJ
Click here to add this to my saved trials
210 W Walnut St
Canton, Illinois 61520
309-647-5240
Principal Investigator: James L. Wade
Phone: 217-876-4740
Illinois CancerCare - Canton Illinois CancerCare is one of the largest private oncology and hematology...
?
mi
from
Canton, IL
Click here to add this to my saved trials
Canton, Ohio 44708
Principal Investigator: Mitchell Haut
Phone: 888-293-4673
?
mi
from
Canton, OH
Click here to add this to my saved trials
2600 Sixth St. SW
Canton, Ohio 44710
330.363.4908
Principal Investigator: Kisa E. Weeman
Phone: 330-363-6891
Aultman Health Foundation The Aultman Foundation will raise and administer funds in order to support...
?
mi
from
Canton, OH
Click here to add this to my saved trials
211 Saint Francis Drive
Cape Girardeau, Missouri 63703
573-331-3000
Saint Francis Medical Center Saint Francis Medical Center is a 282-bed facility serving more than...
?
mi
from
Cape Girardeau, MO
Click here to add this to my saved trials
789 Mt Auburn Rd
Cape Girardeau, Missouri 63703
(573) 519-4725
Southeast Cancer Center SoutheastHEALTH is a far-reaching network of providers and facilities including Southeast Hospital...
?
mi
from
Cape Girardeau, MO
Click here to add this to my saved trials
Carlisle, Pennsylvania 17015
Principal Investigator: David F. Claxton
Phone: 717-531-3779
?
mi
from
Carlisle, PA
Click here to add this to my saved trials
160 S Adams St
Carthage, Illinois 62321
(217) 357-6877
Principal Investigator: James L. Wade
Phone: 217-876-4740
Illinois CancerCare - Carthage Illinois CancerCare, P.C. is a comprehensive practice treating patients withcancer andblood...
?
mi
from
Carthage, IL
Click here to add this to my saved trials
6501 E 2nd St
Casper, Wyoming 82609
(307) 235-5433
Rocky Mountain Oncology Rocky Mountain Oncology Center is a spacious, comfortable, state-of-the-art 19,000 square foot...
?
mi
from
Casper, WY
Click here to add this to my saved trials
Cedar Rapids, Iowa 52403
?
mi
from
Cedar Rapids, IA
Click here to add this to my saved trials
?
mi
from
Cedar Rapids, IA
Click here to add this to my saved trials
3110 MacCorkle Avenue Southeast
Charleston, West Virginia 25304
?
mi
from
Charleston, WV
Click here to add this to my saved trials
303 East Superior Street
Chicago, Illinois 60611
Principal Investigator: Olga Frankfurt
Phone: 312-695-6189
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Chicago, Illinois 60631
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Chicago, Illinois 60640
Principal Investigator: Stuart A. Krauss
Phone: 773-564-5044
?
mi
from
Chicago, IL
Click here to add this to my saved trials
676 N St Clair St #2140
Chicago, Illinois 60611
(312) 664-5400
Hematology and Oncology Associates Northwestern Medical Faculty Foundation (the Foundation) is a premier, multi-specialty physician...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
5841 S Maryland Ave
Chicago, Illinois 60637
1-773-702-6180
Principal Investigator: Andrew S. Artz
Phone: 773-834-7424
University of Chicago Comprehensive Cancer Center The University of Chicago Comprehensive Cancer Center (UCCCC) is...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
12961 27th Ave
Chippewa Falls, Wisconsin 54729
715-738-3700
Marshfield Clinic - Chippewa Center The 15,000 square foot Lake Hallie Center provides urgent care...
?
mi
from
Chippewa Falls, WI
Click here to add this to my saved trials
Cincinnati, Ohio 45220
Principal Investigator: Mehmet S. Copur
Phone: 800-998-2119
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Cincinnati, Ohio 45247
Principal Investigator: Mehmet S. Copur
Phone: 800-998-2119
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Cincinnati, Ohio 45255
Principal Investigator: Mehmet S. Copur
Phone: 800-998-2119
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
9280 SE Sunnybrook Blvd #100
Clackamas, Oregon 97015
(503) 513-3300
Clackamas Radiation Oncology Center State-of-the-art technology and compassionate care come together at Clackamas Radiation Oncology...
?
mi
from
Clackamas, OR
Click here to add this to my saved trials
10900 Euclid Ave
Cleveland, Ohio 44106
216-368-2000
Case Western Reserve Univ Continually ranked among America's best colleges, Case Western Reserve University has...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
2500 Metrohealth Dr
Cleveland, Ohio 44109
(216) 778-7800
MetroHealth Med Ctr The MetroHealth System is one of the largest, most comprehensive health care...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
Clinton, North Carolina 28328
Principal Investigator: James N. Atkins
Phone: 919-580-0000
?
mi
from
Clinton, NC
Click here to add this to my saved trials
Clive, Iowa 50325
Principal Investigator: Mehmet S. Copur
Phone: 800-998-2119
?
mi
from
Clive, IA
Click here to add this to my saved trials
12495 University Ave
Clive, Iowa 50325
(515) 358-9700
Principal Investigator: Mehmet S. Copur
Phone: 800-998-2119
Mercy Cancer Center - West Lakes When it comes to cancer care, there
?
mi
from
Clive, IA
Click here to add this to my saved trials
?
mi
from
Clyde, OH
Click here to add this to my saved trials
6001 E Woodmen Rd
Colorado Springs, Colorado 80923
(719) 776-5000
Penrose-Saint Francis Healthcare Founded by the Sisters of St. Francis and the Sisters of Charity,...
?
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Colorado Springs, Colorado 80907
?
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
1 Hospital Dr
Columbia, Missouri 65212
(573) 882-2100
Principal Investigator: Clint D. Kingsley
Phone: 573-882-7440
University of Missouri-Ellis Fischel Ellis Fischel Cancer Center's team of physician specialists and other trained...
?
mi
from
Columbia, MO
Click here to add this to my saved trials
4050 Coon Rapids Blvd NW
Coon Rapids, Minnesota 55433
(763) 236-6000
Principal Investigator: Patrick J. Flynn
Phone: 952-993-1517
Mercy Hospital Mercy Hospital, located in Coon Rapids, Minnesota, is a 271-bed non-profit hospital that...
?
mi
from
Coon Rapids, MN
Click here to add this to my saved trials
Coos Bay, Oregon 97420
Principal Investigator: Keith S. Lanier
Phone: 503-216-6324
?
mi
from
Coos Bay, OR
Click here to add this to my saved trials